The primary objective is to assess the safety, immunogenicity and efficacy of one of
three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser
applications for the treatment of subjects with primary choroidal melanoma.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03052127.
This is a phase 1B/2 open-label, ascending single and repeat dose clinical trial designed
to evaluate the safety and efficacy of Light-activated AU-011 for the treatment of
subjects with small primary choroidal melanoma.
Throughout the study, subjects will be monitored through medical and ophthalmic
assessments. Subjects will be followed for a total of 2 years.
Lead OrganizationAura Biosciences Inc
